Regenerex Pharma Secures Exclusive Licensing Agreement with Holista Colltech for Advanced Wound Care
Reuters
Sep 04, 2025
Regenerex Pharma Secures Exclusive Licensing Agreement with <a href="https://laohu8.com/S/HCT.AU">Holista Colltech</a> for Advanced Wound Care
Regenerex Pharma Inc. has announced a significant new contract with Holista Colltech Ltd., a globally recognized producer of high-purity ovine collagen. The agreement grants Regenerex exclusive worldwide rights to market Holista's collagen products for wound care applications, initially focusing on the United States market before expanding internationally. Under the agreement, Holista will manufacture and supply its proprietary ovine collagen, including patented 300 kDa intact collagen and nano-collagen technologies. Regenerex has committed to purchase a minimum of USD50,000 in 2025, with the amount scaling up to USD9 million annually by 2028. The partnership involves joint innovation efforts and the conduct of clinical studies and regulatory approvals, aiming to advance wound care solutions globally.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenerex Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001472375-25-000103), on September 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.